Chào mừng trở lại
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Tham gia Cointime
Đã có tài khoản?
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Đăng nhập với email
Đăng nhập với
Email của bạn
Đăng ký
Bấm vào liên kết chúng tôi gửi tới để đăng nhập
Nhấp vào liên kết chúng tôi đã gửi tới để đăng ký.
Chinook Therapeutics
company
About
Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science.
- 11 - 50
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $106M
- Industries
- Biotechnology
- Founded date
- Jan 1, 2019
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Chinook Therapeutics is a biotechnology company that specializes in the fields of therapeutics and life science. The company focuses on developing precision medicines for kidney diseases. Its services offers utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.The company was founded in 2019 and headquartered in Alberta, Canada.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$171M
Chinook Therapeutics has raised a total of
$171M
in funding over 2 rounds. Their latest funding was raised on
Aug 18, 2020 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 18, 2020 | Post-IPO Equity | $106M | 2 | — | — | Detail |
| Aug 22, 2019 | Series A | $65M | 1 |
Versant Ventures
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
2
Chinook Therapeutics is funded by 2 investors.
Northleaf Capital Partners
and Versant Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Northleaf Capital Partners
|
— | Post-IPO Equity |
|
Versant Ventures
|
— | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
